Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Banco Bilbao Vizcaya Argentaria SA (BBVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Banco Bilbao Vizcaya Argentaria SA — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $220.35 (market cap $29.60B), while Banco Bilbao Vizcaya Argentaria SA trades at $28.72 (market cap $157.51B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 5.3× Alnylam Pharmaceuticals, Inc.'s market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 3.8% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BBVA | |
|---|---|---|
Market Cap | $29.60B | $157.51B |
Sector | Health | Financials |
52-Week High | $491.22 | $28.50 |
52-Week Low | $205.48 | $17.96 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 3.8% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →
